Sustained exogenous expression of therapeutic levels of IFN-γ ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2729-2735

  Hattori, Kayoko ^a   Nishikawa, Makiya ^a   Watcharanurak, Kanitta ^a   Ikoma, Akihiko ^a   Kabashima, Kenji ^a   Toyota, Hiroyasu ^a   Takahashi, Yuki ^a   Takahashi, Rei ^b   Watanabe, Yoshihiko ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; PLASMID VECTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; CPG ISLAND; DISEASE SEVERITY; EOSINOPHIL; GENE EXPRESSION; GENE TRANSFER; GENETIC ASSOCIATION; GENETIC CODE; HYDRODYNAMICS BASED TRANSFECTION; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCRATCHING; SKIN WATER LOSS; SKINFOLD; SPLEEN; TH1 CELL; ANIMAL; BLOOD; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; METHODOLOGY; MOUSE STRAIN; PATHOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN;

ANIMALS; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOGLOBULIN E; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-13; INTERLEUKIN-17; INTERLEUKIN-4; INTERLEUKIN-5; LYMPHOCYTE COUNT; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TH1 CELLS;

EID: 77951888091     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900215     Document Type: Article

References (44)

1. Romagnani, S. 2004. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 112: 352-363.
2. Grewe, M., C. A. Bruijnzeel-Koomen, E. Schöpf, T. Thepen, A. G. Langeveld-Wildschut, T. Ruzicka, and J. Krutmann. 1998. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol. Today 19: 359-361. (Pubitemid 28392277)
3. Spergel, J. M., E. Mizoguchi, H. Oettgen, A. K. Bhan, and R. S. Geha. 1999. Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J. Clin. Invest. 103: 1103-1111.
4. Vestergaard, C., H. Yoneyama, M. Murai, K. Nakamura, K. Tamaki, Y. Terashima, T. Imai, O. Yoshie, T. Irimura, H. Mizutani, and K. Matsushima. 1999. Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J. Clin. Invest. 104: 1097-1105.
5. Furue, M. 1994. Atopic dermatitis - immunological abnormality and its background. J. Dermatol. Sci. 7: 159-168.
6. Grassegger, A., and R. Höpfl. 2004. Significance of the cytokine interferon gamma in clinical dermatology. Clin. Exp. Dermatol. 29: 584-588.
7. Ellis, C. N., S. R. Stevens, B. K. Blok, R. S. Taylor, and K. D. Cooper. 1999. Interferon-γ therapy reduces blood leukocyte levels in patients with atopic dermatitis: correlation with clinical improvement. Clin. Immunol. 92: 49-55.
8. Jang, I. G., J. K. Yang, H. J. Lee, J. Y. Yi, H. O. Kim, C. W. Kim, and T. Y. Kim. 2000. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J. Am. Acad. Dermatol. 42: 1033-1040.
9. Stevens, S. R., J. M. Hanifin, T. Hamilton, S. J. Tofte, and K. D. Cooper. 1998. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch. Dermatol. 134: 799-804.
10. Noh, G. W., and K. Y. Lee. 1998. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 53: 1202-1207.
11. Younes, H. M., and B. G. Amsden. 2002. Interferon-γ therapy: evaluation of routes of administration and delivery systems. J. Pharm. Sci. 91: 2-17.
12. Chen, F. M., Y. M. Zhao, H. Wu, Z. H. Deng, Q. T. Wang, W. Zhou, Q. Liu, G. Y. Dong, K. Li, Z. F. Wu, and Y. Jin. 2006. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran-co-gelatin microspheres. J. Control. Release 114: 209-222.
13. Gu, F., H. M. Younes, A. O. El-Kadi, R. J. Neufeld, and B. G. Amsden. 2005. Sustained interferon-γ delivery from a photocrosslinked biodegradable elastomer. J. Control. Release 102: 607-617. (Pubitemid 40170204)
14. Howell, S. B. 2001. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J. 7: 219-227.
15. Qiu, J., X. H. Wei, F. Geng, R. Liu, J. W. Zhang, and Y. H. Xu. 2005. Multivesicular liposome formulations for the sustained delivery of interferon α-2b. Acta Pharmacol. Sin. 26: 1395-1401.
16. Harris, J. M., N. E. Martin, and M. Modi. 2001. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40: 539-551.
17. Hyoudou, K., M. Nishikawa, Y. Kobayashi, Y. Umeyama, F. Yamashita, and M. Hashida. 2006. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic. Biol. Med. 41: 1449-1458.
18. Nishikawa, M., K. Hyoudou, Y. Kobayashi, Y. Umeyama, Y. Takakura, and M. Hashida. 2005. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J. Control. Release 109: 101-107. (Pubitemid 41737256)
19. Pepinsky, R. B., R. I. Shapiro, S. Wang, A. Chakraborty, A Gill, D. J. Lepage, D. Wen, P. Rayhorn, G. S. Horan, F. R. Taylor, et al. 2001. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. J Pharmacol. Exp. Ther. 297: 1059-1066.
20. Kobayashi, N., T. Kuramoto, S. Chen, Y. Watanabe, and Y. Takakura. 2002. Therapeutic effect of intravenous interferon gene delivery with naked plasmid DNA in murine metastasis models. Mol. Ther. 6: 737-744.
21. Kawano, H., M. Nishikawa, M. Mitsui, Y. Takahashi, K. Kako, K. Yamaoka, Y. Watanabe, and Y. Takakura. 2007. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA. Int. J. Cancer 121: 401-406. (Pubitemid 46924040)
22. Mitsui, M., M. Nishikawa, L. Zang, M. Ando, K. Hattori, Y. Takahashi, Y. Watanabe, and Y. Takakura. 2009. Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J. Gene Med. 11: 435-443.
23. Matsuda, H., N. Watanabe, G. P. Geba, J. Sperl, M. Tsudzuki, J. Hiroi, M. Matsumoto, H. Ushio, S. Saito, P. W. Askenase, and C. Ra. 1997. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int. Immunol. 9: 461-466.
24. Nomura, T., K. Yasuda, T. Yamada, S. Okamoto, R. I. Mahato, Y. Watanabe, Y. Takakura, and M. Hashida. 1999. Gene expression and antitumor effects following direct interferon (IFN)-γ gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Ther. 6: 121-129. (Pubitemid 29043702)
25. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266. (Pubitemid 29359019)
26. Kobayashi, N., M. Nishikawa, and Y. Takakura. 2005. The hydrodynamics-based procedure for controlling the pharmacokinetics of gene medicines at whole body, organ and cellular levels. Adv. Drug Deliv. Rev. 57: 713-731.
27. Kuraishi, Y., T. Nagasawa, K. Hayashi, and M. Satoh. 1995. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur. J. Pharmacol. 275: 229-233.
28. Mamessier, E., and A. Magnan. 2006. Cytokines in atopic diseases: revisiting the Th2 dogma. Eur. J. Dermatol. 16: 103-113.
29. Bos, J. D., E. J. Van Leent, and J. H. Sillevis Smitt. 1998. The millennium criteria for the diagnosis of atopic dermatitis. Exp. Dermatol. 7: 132-138.
30. Punnonen, J., H. Yssel, and J. E. de Vries. 1997. The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J. Allergy Clin. Immunol. 100: 792-801.
31. Yew, N. S., H. Zhao, M. Przybylska, I. H. Wu, J. D. Tousignant, R. K. Scheule, and S. H. Cheng. 2002. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol. Ther. 5: 731-738.
32. Chomarat, P., M. C. Rissoan, J. Banchereau, and P. Miossec. 1993. Interferon γ inhibits interleukin 10 production by monocytes. J. Exp. Med. 177: 523-527.
33. Xiao, T., H. Fujita, H. Saeki, H. Mitsui, M. Sugaya, Y. Tada, T. Kakinuma, H. Torii, K. Nakamura, A. Asahina, and K. Tamaki. 2003. Thymus and activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal Langerhans cells is upregulated by TNF-α and IL-4 and downregulated by IFN-γ. Cytokine 23: 126-132.
34. Mori, T., K. Kabashima, R. Yoshiki, K. Sugita, N. Shiraishi, A. Onoue, E. Kuroda, M. Kobayashi, U. Yamashita, and Y. Tokura. 2008. Cutaneous hypersensitivities to hapten are controlled by IFN-γ-upregulated keratinocyte Th1 chemokines and IFN-γ-downregulated langerhans cell Th2 chemokines. J. Invest. Dermatol. 128: 1719-1727.
35. Iwamoto, I., H. Nakajima, H. Endo, and S. Yoshida. 1993. Interferon γ regulates antigen-induced eosinophil recruitment into the mouse airways by inhibiting the infiltration of CD4+ T cells. J. Exp. Med. 177: 573-576.
36. Park, C. S., E. N. Choi, J. S. Kim, Y. S. Choi, T. Y. Rhim, H. S. Chang, and I. Y. Chung. 2005. Interferon-γ inhibits in vitro mobilization of eosinophils by interleukin-5. Int. Arch. Allergy Immunol. 136: 295-302.
37. Luster, A. D. 1998. Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338: 436-445.
38. Kim, C. H., and H. E. Broxmeyer. 1999. Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J. Leukoc. Biol. 65: 6-15.
39. Del Prete, G. 1992. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 47: 450-455.
40. Kobayashi, N., M. Nishikawa, K. Hirata, and Y. Takakura. 2004. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J. Gene Med. 6: 584-592. (Pubitemid 40228074)
41. Jacobs, F., J. Snoeys, Y. Feng, E. Van Craeyveld, J. Lievens, D. Armentano, S. H. Cheng, and B. De Geest. 2008. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther. 15: 594-603.
42. Nishikawa, M., A. Nakayama, Y. Takahashi, Y. Fukuhara, and Y. Takakura. 2008. Reactivation of silenced transgene expression in mouse liver by rapid, large-volume injection of isotonic solution. Hum. Gene Ther. 19: 1009-1020.
43. Khorsandi, S. E., P. Bachellier, J. C. Weber, M. Greget, D. Jaeck, D. Zacharoulis, C. Rountas, S. Helmy, A. Helmy, M. Al-Waracky, et al. 2008. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther. 15: 225-230.
44. Suda, T., K. Suda, and D. Liu. 2008. Computer-assisted hydrodynamic gene delivery. Mol. Ther. 16: 1098-1104.